Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Embrex - EMBX -- Ignore unavailable to you. Want to Upgrade?

To: John Liu who wrote (40)	9/6/1998 9:25:00 AM
From: DIY Investor	Read Replies (1) \| Respond to of 59

EMBX can be a good defensive stock in the current environment. I also like EMBX and picked up shares went it went below $5. Zeitgeist, I believe that the Invoject(R) devices are leased at a low cost rather than being provided free. John, although, it may be less expensive in low-labor cost countries to innouculate manually, I think most larger poultry companies would opt for the Invoject(R) method. There is also Europe in which the company still hasn't made a stronghold. Significant revenue growth will be had once the various vaccines, being sought, are developed. The information below came from the company's last 10k. In addition to the INOVOJECT(R) system, Embrex has developed and is marketing its Viral Neutralizing Factor ("VNF(R)") antibody, useful in the development of certain avian vaccines. The Company also has developed and is marketing Bursaplex(TM), a VNF(R)-based vaccine for protection against avian Infectious Bursal Disease ("IBD"). Embrex also is developing various other proprietary pharmaceutical and biological products to improve bird health, reduce bird production costs and provide other economic benefits to the poultry industry. These compounds include vaccines, immune enhancers, performance modifiers and genetic materials designed to increase poultry productivity and health while reducing costs. These products are in various stages of development, and some are being developed in collaboration with major drug companies, the United States Department of Agriculture (the "USDA"), and several leading universities in the field of avian science. These compounds are being designed to be delivered through the INOVOJECT(R) system, and some may also be administered via post-hatch injection